Dr. Alan B. Goldsobel, MD

Dr. Goldsobel practices at Allergy And Asthma Associates Of Northern California A Medical Corp in San Jose, California.

Dr. Goldsobel's NPI, 1063528321, was assigned on August 21, 2006. Dr. Goldsobel graduated from UTMB Health in 1977. Dr. Goldsobel holds California license G39891.

Dr. Goldsobel's primary practice is Allergy and Asthma Associates of Northern California A Medical Corp, at 4050 Moorpark Ave, San Jose, CA 95117. The practice phone is (408) 243-2700.

Dr. Goldsobel's primary practice is Allergy And Asthma Associates Of Northern California A Medical Corp in San Jose, California. Dr. Goldsobel is also affiliated with Dignity Health - Dominican Hospital. The medical group on file is Stanford Health Care. Dmand AI also links Dr. Goldsobel to 3 more medical groups and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Goldsobel practices, 3 sites in all. Vendor and product names are available with a free account.

Allergy and immunology is Dr. Goldsobel's primary specialty in the NPI Registry, under taxonomy code 207K00000X. Dr. Goldsobel is board certified in allergy & immunology by the American Board of Allergy and Immunology. Dr. Goldsobel is licensed in California.

Dmand AI lists acute sinusitis, asthma, chronic nasal allergies, hives and immune deficiency disease among the conditions Dr. Goldsobel treats.

CMS data shows 4,425 Medicare services from Dr. Goldsobel across 11 procedure codes in 2024, for 287 Medicare patients. Medicare paid $68,598 for them. Every service was in an office.

CMS counts 287 Medicare patients who saw Dr. Goldsobel in 2024. The largest group is 65 to 74, with 136 patients. 75% of them have high cholesterol, and 64% have high blood pressure. Their average risk score is 0.89, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Goldsobel's median patient age at 41, with 53% women.

In 2024, Dr. Goldsobel wrote 1,450 Medicare Part D claims for 254 patients. 57% of them were for generic drugs. CMS names the drug for 1,239 of them, across 31 drugs with 11 or more claims each, at $742,834 in total drug cost. In 2023, CMS named 1,207 claims across 27 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 82 out of 100 for Dr. Goldsobel for performance year 2024, reported as part of a group. Dr. Goldsobel accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Goldsobel as offering telehealth.

Dmand AI links 24 papers to Dr. Goldsobel, published from 2019 to 2022. 2019 was the busiest year, with 2. The most frequent topics are Double-Blind Method, Asthma and Rhinitis, Allergic, Seasonal. Dr. Goldsobel has published most often in Ann Allergy Asthma Immunol. Dr. Goldsobel's most frequent co-authors are Eli Owen Meltzer, MD, Ewald Richard Stiehm, MD and Aikaterini Anagnostou, MD, PhD.

Dmand AI links Dr. Goldsobel to 103 clinical trials, 7 of them phase 2 studies. 7 are still active or recruiting. Conditions studied include Out-of-Hospital Cardiac Arrest, Frailty and Hyperglycemia. University of Aarhus sponsors the most, 4.

CMS Open Payments shows 621 general payments to Dr. Goldsobel from 35 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 48% of the total. GlaxoSmithKline, LLC. paid the most, $30,700. It also lists 3 research payments totaling $53,450 in 2016.

Dmand AI lists 7 awards for Dr. Goldsobel, most recently Best Doctors in 2019.

Dr. Goldsobel graduated from UTMB Health in 1977. Dr. Goldsobel is a member of AAAAI and AAP.

Dr. Goldsobel is in network with 15 carriers, including Aetna, Elevance and Blue Cross Blue Shield of Michigan. PPO plans come from the most carriers, 10. Check the plan with the practice before a visit.